探讨PD-1和PD-L1蛋白在胃癌组织中的表达及其临床意义
|
摘要
目的探讨胃癌组中程序性死亡受体-1(PD-1)及其配体(PD-L1)蛋白表达情况及其临床意义。方法选择2014年6月—2018年8月在该院行胃癌根治术的胃癌患者的石蜡标本66例为观察组,并随机选取肿瘤组织>5 cm的癌旁组织60例为对照组。比较两组PD-1和PD-L1表达情况,分析两者在胃癌组织中表达与临床病理因素关系。结果观察组中PD-1和PD-L1阳性表达率分别为66.67%(44/66)、40.91%(27/66),对照组中无PD-1和PD-L1蛋白表达,差异有统计学意义(χ2=61.463、31.240,P=0.000);胃癌间质中PD-L1表达与淋巴结转移有关;胃癌细胞中PD-L1表达与浸润层面、脉管癌栓、淋巴结转移、p TNM分期有关(P<0.05);胃癌组织中PD-1表达与患者各临床病理因素无关(P>0.05)。结论 PD-1和PD-L1蛋白在胃癌组织中表达显著升高,而PD-L1与患者临床病理特征关系密切,可将其作为胃癌治疗的新靶点。
Objective To investigate the expression and clinical significance of programmed death receptor-1(PD-1) and its ligand(PDL1) protein in gastric cancer. Methods 66 patients with paraffin-embedded specimens of gastric cancer who underwent radical gastrec-tomy in our hospital from June 2014 to August 2018 were selected as observation group, and 60 cases of adjacent tissues with tumor tissue >5 cm were randomly selected as the control group. The expressions of PD-1 and PD-L1 were compared between the two groups, and the relationship between the expression of PD-1 and PD-L1 in gastric cancer tissues was analyzed. Results The positive expression rates of PD-1 and PD-L1 in the observation group were 66.67%(44/66) and 40.91%(27/66), respectively. There was no PD-1 and PD-L1 protein expression in the control group. The difference was statistically significant. Significance( χ2=61.463, 31.240,P=0.000); PD-L1 expression in gastric cancer stroma was associated with lymph node metastasis; PD-L1 expression in gastric cancer cells was associated with invasive level, vascular tumor thrombus, lymph node metastasis, pTNM staging(P<0.05); PD-1 expression in gastric cancer tissues was not associated with clinical pathological factors(P>0.05). Conclusion The expression of PD-1 and PD-L1 protein is significantly increased in gastric cancer tissues, and PD-L1 is closely related to the clinicopathological features of patients.It can be used as a new target for the treatment of gastric cancer.
Objective To investigate the expression and clinical significance of programmed death receptor-1(PD-1) and its ligand(PDL1) protein in gastric cancer. Methods 66 patients with paraffin-embedded specimens of gastric cancer who underwent radical gastrec-tomy in our hospital from June 2014 to August 2018 were selected as observation group, and 60 cases of adjacent tissues with tumor tissue >5 cm were randomly selected as the control group. The expressions of PD-1 and PD-L1 were compared between the two groups, and the relationship between the expression of PD-1 and PD-L1 in gastric cancer tissues was analyzed. Results The positive expression rates of PD-1 and PD-L1 in the observation group were 66.67%(44/66) and 40.91%(27/66), respectively. There was no PD-1 and PD-L1 protein expression in the control group. The difference was statistically significant. Significance( χ2=61.463, 31.240,P=0.000); PD-L1 expression in gastric cancer stroma was associated with lymph node metastasis; PD-L1 expression in gastric cancer cells was associated with invasive level, vascular tumor thrombus, lymph node metastasis, pTNM staging(P<0.05); PD-1 expression in gastric cancer tissues was not associated with clinical pathological factors(P>0.05). Conclusion The expression of PD-1 and PD-L1 protein is significantly increased in gastric cancer tissues, and PD-L1 is closely related to the clinicopathological features of patients.It can be used as a new target for the treatment of gastric cancer.
引文
[1]陶凯,董剑宏.程序性死亡受体1及其配体在胃癌免疫治疗中的研究进展[J].肿瘤研究与临床,2018,30(1):69-72.
[2]刘洋,王晋芬,李雪薇,等.胃癌组织中PD-L1蛋白表达和基因扩增的相关性[J].中华病理学杂志,2018,47(8):597-602.
[3]钮佳宁,梁俏美,沈佳程,等.PD-L1表达与胃癌发生发展的相关性Meta分析[J].中国免疫学杂志,2018,34(8):1211-1216.
[4]卓静,时瑶.胃癌患者PD-L1、B7-H3的表达与肿瘤病理特征和预后的关系研究[J].西南国防医药,2016,26(6):602-605.
[5]刘永军,徐稳.肿瘤免疫治疗中PD-1/PD-L1抑制剂的研究进展[J].中国医药导报,2018,15(16):38-41.
[6]张绪超.PD-1/PD-L1免疫检查点抑制剂抗肿瘤治疗的潜在临床生物标志物[J].中华医学杂志,2017,97(32):2551-2554.
[7]任中华.PD-1/PD-L1在结直肠癌中的研究进展[J].中国肿瘤生物治疗杂志,2017,24(10):1134-1138.
[8]韦炜,蒋敬庭,吴昌平.胃癌中PD-L1的表达及PD-1/PD-L1抑制剂应用研究进展[J].临床检验杂志,2017,35(5):363-365.
[9]汪超,陈志红,魏法星,等.程序性死亡配体1在胃癌组织中的表达及其临床意义[J].江苏大学学报:医学版,2017,27(2):158-161.
[10]孙志佳,杜楠.免疫检查点阻断在晚期胃癌的治疗进展[J].海南医学院学报,2017,23(12):1733-1736.
[11]杨莹,白春梅,孙昭.抗PD-1/PD-L1药物治疗肿瘤耐药机制研究进展[J].癌症进展,2017,15(12):1365-1368.
[12]李毓飞,鲍芳,项颖,等.胃癌组织中PD-1/PD-L1的表达与临床病理特征及预后的相关性[J].临床与实验病理学杂志,2018,34(6):614-618.
[2]刘洋,王晋芬,李雪薇,等.胃癌组织中PD-L1蛋白表达和基因扩增的相关性[J].中华病理学杂志,2018,47(8):597-602.
[3]钮佳宁,梁俏美,沈佳程,等.PD-L1表达与胃癌发生发展的相关性Meta分析[J].中国免疫学杂志,2018,34(8):1211-1216.
[4]卓静,时瑶.胃癌患者PD-L1、B7-H3的表达与肿瘤病理特征和预后的关系研究[J].西南国防医药,2016,26(6):602-605.
[5]刘永军,徐稳.肿瘤免疫治疗中PD-1/PD-L1抑制剂的研究进展[J].中国医药导报,2018,15(16):38-41.
[6]张绪超.PD-1/PD-L1免疫检查点抑制剂抗肿瘤治疗的潜在临床生物标志物[J].中华医学杂志,2017,97(32):2551-2554.
[7]任中华.PD-1/PD-L1在结直肠癌中的研究进展[J].中国肿瘤生物治疗杂志,2017,24(10):1134-1138.
[8]韦炜,蒋敬庭,吴昌平.胃癌中PD-L1的表达及PD-1/PD-L1抑制剂应用研究进展[J].临床检验杂志,2017,35(5):363-365.
[9]汪超,陈志红,魏法星,等.程序性死亡配体1在胃癌组织中的表达及其临床意义[J].江苏大学学报:医学版,2017,27(2):158-161.
[10]孙志佳,杜楠.免疫检查点阻断在晚期胃癌的治疗进展[J].海南医学院学报,2017,23(12):1733-1736.
[11]杨莹,白春梅,孙昭.抗PD-1/PD-L1药物治疗肿瘤耐药机制研究进展[J].癌症进展,2017,15(12):1365-1368.
[12]李毓飞,鲍芳,项颖,等.胃癌组织中PD-1/PD-L1的表达与临床病理特征及预后的相关性[J].临床与实验病理学杂志,2018,34(6):614-618.